Imaging neurodegeneration in Parkinson's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 7, 2009, Pages 722-729

  Pavese, Nicola ^a   Brooks, David J ^a  

^a MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

Author keywords

Imaging; MRI; Neurodegeneration; Parkinson's disease; PET

Indexed keywords

6 FLUORODOPA F 18; AMINO ACID DECARBOXYLASE; CEP 1347; CHOLINESTERASE INHIBITOR; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCOSE; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RILUZOLE; ROPINIROLE; VESICULAR MONOAMINE TRANSPORTER 2;

ALZHEIMER DISEASE; CELL TRANSPLANTATION; CLINICAL TRIAL; DEMENTIA; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; NERVE DEGENERATION; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

PARKINSONIA;

EID: 68649126827     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2008.10.003     Document Type: Review

References (93)

1. de Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baldereschi M., Fratiglioni L., Lobo A., Martinez-Lage J., Trenkwalder C., and Hofman A. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts, Neurologic Diseases in the Elderly Research Group. Neurology 54 11 Suppl. 5 (2000) S21-S23
2. Sato K., Hatano T., Yamashiro K., Kagohashi M., Nishioka K., Izawa N., Mochizuki H., Hattori N., Mori H., Mizuno Y., and Juntendo Parkinson Study Group. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Mov. Disord. 21 (2006) 1384-1395
3. Braak H., Ghebremedhin E., Rub U., Bratzke H., and Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell. Tissue Res. 318 (2004) 121-134
4. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
5. Banati R.B. Visualising microglial activation in vivo. Glia 40 (2002) 206-217
6. Snow B.J., Tooyama I., McGeer E.G., Yamada T., Calne D.B., Takahashi H., and Kimura H. Human positron emission tomographic 18F-dopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 34 (1993) 324-330
7. Pate B.D., Kawamata T., Yamada T., McGeer E.G., Hewitt K.A., Snow B.J., Ruth T.J., and Calne D.B. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 34 (1993) 331-338
8. Ribeiro M.J., Vidailhet M., Loch C Dupel C., Nguyen J.P., Ponchant M., Dolle F., Peschanski M., Hantraye P., Cesaro P., Samson Y., and Remy P. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch. Neurol. 59 (2002) 580-586
9. Brooks D.J., Salmon E.P., Mathias C.J., Quinn N., Leenders K.L., Bannister R., Marsden C.D., and Frackowiak R.S. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure and Parkinson's disease studied by PET. Brain 113 (1990) 1539-1552
10. Vingerhoets F.J.G., Schulzer M., Calne D.B., and Snow B.J. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Ann. Neurol. 41 (1997) 58-64
11. Broussolle E., Dentresangle C., Landais P., Garcia-Larrea L., Pollak P., Croisile B., Hibert O., Bonnefoi F., Galy G., Froment J.C., and Comar D. The relation of putamen and caudate nucleus 18F-dopa uptake to motor and cognitive performances in Parkinson's disease. J. Neurol. Sci. 166 (1999) 141-151
12. Morrish P.K., Sawle G.V., and Brooks D.J. Clinical and [18F] dopa PET findings in early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 59 (1995) 597-600
13. Kish S.J., Shannak K., and Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318 (1988) 876-880
14. Rakshi J.S., Uema T., Ito K., Bailey D.L., Morrish P.K., Ashburner J., Dagher A., Jenkins I.H., Friston K.J., and Brooks D.J. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease. A 3D [18F]Dopa-PET study. Brain 122 (1999) 1637-1650
15. Kaasinen V., Nurmi E., Brück A., Eskola O., Bergman J., Solin O., and Rinne J.O. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 124 (2001) 1125-1130
16. Whone A.L., Moore R.Y., Piccini P., and Brooks D.J. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann. Neurol. 53 (2003) 206-213
17. Seibyl J.P., Marek K.L., Quinlan D., Sheff K., Zoghbi S., Zea-Ponce Y., Baldwin R.M., Fussell B., Smith E.O., Charney D.S., Hoffer P.B., and Innis R.B. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol. 38 (1995) 589-598
18. Brucke T., Asenbaum S., Pirker W., Djamshidian S., Wenger S., Wober C., Muller C., and Podreka I. Measurement of dopaminergic degeneration in Parkinson's disease with [123I]beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J. Neural Transm. 50 (1997) 9-24
19. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?. Mov. Disord. 7 18 Suppl. (2003) S43-S51
20. Pirker W., Asenbaum S., Hauk M., Kandlhofer S., Tauscher J., Willeit M., Neumeister A., Praschak-Rieder N., Angelberger P., and Brucke T. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J. Nucl. Med. 41 (2000) 36-44
21. van Dyck C.H., Seibyl J.P., Malison R.T., Laruelle M., Wallace E., Zoghbi S.S., Zea-Ponce Y., Baldwin R.M., Charney D.S., and Hoffer P.B. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J. Nucl. Med. 36 (1995) 1175-1181
22. Tissingh G., Bergmans P., Booij J., Winogrodzka A., Stoof J.C., Wolters E.C., and Van Royen E.A. [123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. Eur. J. Nucl. Med. 24 (1997) 1171-1174
23. Liu Y., and Edwards R.H. The role of the vescicular transport proteins in the synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20 (1997) 125-156
24. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., Wudel J., Pal P.K., de la Fuente-Fernandez R., Calne D.B., and Stoessl A.J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopamine nerve terminals in Parkinson's disease. Ann. Neurol. 47 (2000) 493-503
25. Piccini P., Burn D.J., Ceravolo R., Maraganore D., and Brooks D.J. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann. Neurol. 45 (1999) 82-577
26. Piccini P., Morrish P.K., Turjanski N., Sawle G.V., Burn D.J., Weeks R.A., Mark M.H., Maraganore D.M., Lees A.J., and Brooks D.J. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa PET study. Ann. Neurol. 41 (1997) 222-229
27. Hilker R., Klein C., Hedrich K., Ozelius L.J., Vieregge P., Herholz K., Pramstaller P.P., and Heiss W.D. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci. Lett. 19 (2002) 50-54
28. Khan N.L., Scherfler C., Graham E., Bhatia K.P., Quinn N., Lees A.J., Brooks D.J., Wood N.W., and Piccini P. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 64 (2005) 134-136
29. Ponsen M.M., Stoffers D., Booij J., van Eck-Smit B.L., Wolters E.C.h., and Berendse H.W. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol, 56 (2004) 173-181
30. Vingerhoets F.J., Snow B.J., Lee C.S., Schulzer M., Mak E., and Calne D.B. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann. Neurol. 36 (1994) 759-764
31. Morrish P.K., Sawle G.V., and Brooks D.J. An 18F-dopa PET and clinical study of the rate of progression in Parkinson's disease. Brain 119 (1996) 585-591
32. Morrish P.K., Rakshi J.S., Bailey D.L., Sawle G., and Brooks D.J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with 18F-dopa PET. J. Neurol. Neurosurg. Psychiatry 64 (1998) 314-319
33. Nurmi E., Ruottinen H.M., Bergman J., Haaparanta M., Solin O., Sonninen P., and Rinne J.O. Rate of progression in Parkinson's disease: a 18-F-fluoro-dopa PET study. Mov. Disord. 16 (2001) 608-615
34. Brück A., Aalto S., Nurmi E., Vahlberg T., Bergman J., and Rinne J.O. Striatal subregional 6-[18F]fluoro-l-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov. Disord. 21 (2006) 958-963
35. Marek K., Innis R., van Dyck C., Fussell B., Early M., Eberly S., Oakes D., and Seibyl J. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57 (2001) 2089-2094
36. Pirker W., Djamshidian S., Asenbaum S., Gerschlager W., Tribl G., Hoffmann M., and Brucke T. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov. Disord. 17 (2002) 45-53
37. Winogrodzka A., Bergmans P., Booij J., van Royen E.A., Stoof J.C., and Wolters E.C. [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 74 (2003) 294-298
38. Nurmi E., Bergman J., Eskola O., Solin O., Vahlberg T., Sonninen P., and Rinne J.O. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Synapse 48 (2003) 109-115
39. Au W.L., Schulzer M., Sossi V., Ruth T.J., Calne D.B., Stoessl A.J., and Lee C.S. Aging effect on the rate of progression in Parkinson's disease: a four-year longitudinal PET study. Mov. Disord. 19 (2004) S381
40. Buck B.H., Schulzer M., Sossi V., Ruth T.J., Calne D.B., Stoessl A.J., and Lee C.S. Uniform rate of progression in subregions of the putamen in Parkinson's disease: evidence for the dissociation between the etiology and pathogenesis. Neurology 62 (2004) A430-A431
41. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. (056 Study Group). N. Engl. J. Med. 342 (2000) 1484-1491
42. Oertel W.H., Schwarz J., Leenders K.L., et al., on behalf of the Pelmopet-Study Group. Results of a 3 year randomized, double-blind, PET-controlled study of pergolide vs. l-dopa as monotherapy in early Parkinson's disease (PELMOPET-trial). J. Neurol. Sci. 187 Suppl 1 (2001) S444
43. Rakshi J.S., Pavese N., Uema T., Ito K., Morrish P.K., Bailey D.L., and Brooks D.J. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or l-dopa: an 18F-dopa PET study. J. Neural Transm. 109 (2002) 1433-1443
44. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
45. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., Lang A.E., Rascol O., Ribeiro M.J., Remy P., Poewe W.H., Hauser R.A., Brooks D.J., and REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 54 (2003) 93-101
46. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marek K., and Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351 (2004) 2498-2508
47. Pavese N., Rascol O., Olanow W.C., Truffinet P., and Brooks D.J. The effects of riluzole on progression of early Parkinson's disease: an 18F-fluorodopa PET study. Parkinsonism Relat. Disord. 11 Suppl. 2 (2005) 229
48. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., and Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9 (2003) 589-595
49. Brundin P., Pogarell O., Hagell P., Piccini P., Widner H., Schrag A., Kupsch A., Crabb L., Odin P., Gustavii B., Björklund A., Brooks D.J., Marsden C.D., Oertel W.H., Quinn N.P., Rehncrona S., and Lindvall O. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123 (2000) 1380-1390
50. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 51 Suppl. 2 (1998) S2-S9
51. Moore R.Y., Whone A.L., and Brooks D.J. Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study. Neurobiol. Dis. 29 (2008) 381-390
52. Seibyl J.P., Wallace E., Smith E.O., Stabin M., Baldwin R.M., Zoghbi S., Zea-Ponce Y., Gao Y., Zhang W.Y., and Neumeyer J.L. Whole-body biodistribution, radiation absorbed dose, and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects. J. Nucl. Med. 35 (1994) 764-770
53. Kim S.E., Choi J.Y., Choe Y.S., Choi Y., and Lee Y. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. J. Nucl. Med. 44 (2003) 870-876
54. Doder M., Rabiner E.A., Turjanski N., Lees A.J., and Brooks D. Brain serotonin 5HT1A receptor in Parkinson's disease with and without depression measured with positron emission tomography with 11C-WAY100635. Mov. Disord. 15 (2000) 213
55. Guttman M., Boileau I., Warsh J., Saint-Cyr J.A., Ginovart N., McCluskey T., Houle S., Wilson A., Mundo E., Rusjan P., Meyer J., and Kish S.J. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur. J. Neurol, 14 (2007) 523-528
56. Doder M., Rabiner E.A., Turjanski N., Lees A.J., Brooks D.J., and 11C-WAY 100635 PET study. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60 (2003) 601-605
57. Remy P., Doder M., Lees A., Turjanski N., and Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128 (2005) 1314-1322
58. Kuhl D.E., Minoshima S., Fessler J.A., Frey K.A., Foster N.L., Ficaro E.P., Wieland D.M., and Koeppe R.A. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease and Parkinson's disease. Ann. Neurol. 40 (1996) 399-410
59. Hilker R., Thomas A.V., Klein J.C., Weisenbach S., Kalbe E., Burghaus L., Jacobs A.H., Herholz K., and Heiss W.D. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65 (2005) 1716-1722
60. Bohnen N.I., Kaufer D.I., Ivanco L.S., Lopresti B., Koeppe R.A., Davis J.G., Mathis C.A., Moore R.Y., and DeKosky S.T. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease. Arch. Neurol. 60 (2003) 1745-1748
61. Ahmed I., Edison P., Quinn N.P., Walker Z., and Brooks D.J. Amyloid deposition and glucose metabolism in Parkinson's disease dementia (PDD): an [11C]PIB and [18 F]FDG PET study. Mov. Disord. 22 Supp16 (2007) S139-S140
62. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., and Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57 (2005) 168-175
63. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R.B., and Brooks D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21 (2006) 404-412
64. Schrag A., Good C.D., Miszkiel K., Morris H.R., Mathias C.J., Lees A.J., and Quinn N.P. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 54 (2000) 697-702
65. Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P., and Marsden C.D. Increased nigral iron content in postmortem parkinsonian brain. Lancet 2 8569 (1987) 1219-1220
66. Antonini A., Leenders K.L., Meier D., Oertel W.H., Boesiger P., and Anliker M. T2 relaxation time in patients with Parkinson's disease. Neurology 43 (1993) 697-700
67. Vymazal J., Righini A., Brooks R.A., Canesi M., Mariani C., Leonardi M., and Pezzoli G. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 211 (1999) 489-495
68. Hutchinson M., and Raff U. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. Am. J. Neuroradiol. 21 (2000) 697-701
69. Hu M.T., White S.J., Herlihy A.H., Chaudhuri K.R., Hajnal J.V., and Brooks D.J. A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. Neurology 56 (2001) 1195-1200
70. Michaeli S., Oz G., Sorce D.J., Garwood M., Ugurbil K., Majestic S., and Tuite P. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov. Disord. 22 3 (2007) 40-334
71. Martin W.R., Wieler M., and Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70 (2008) 1411-1417
72. Ashburner J., and Friston K.J. Voxel-based morphometry - the methods. NeuroImage 11 (2000) 805-821
73. Burton E.J., McKeith I.G., Burn D.J., Williams E.D., and O'Brien J.T. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 127 (2004) 791-800
74. Summerfield C., Junqué C., Tolosa E., Salgado-Pineda P., Gómez-Ansón B., Martí M.J., Pastor P., Ramírez-Ruíz B., and Mercader J. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch. Neurol. 62 (2005) 281-285
75. Ramírez-Ruiz B., Martí M.J., Tolosa E., Bartrés-Faz D., Summerfield C., Salgado-Pineda P., Gómez-Ansón B., and Junqué C. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. J. Neurol. 252 (2005) 1345-1352
76. Nagano-Saito A., Washimi Y., Arahata Y., Kachi T., Lerch J.P., Evans A.C., Dagher A., and Ito K. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 64 (2005) 224-229
77. Beyer M.K., Janvin C.C., Larsen J.P., and Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J. Neurol. Neurosurg. Psychiatry 78 (2007) 254-259
78. Feldmann A., Illes Z., Kosztolanyi P., Illes E., Mike A., Kover F., Balas I., Kovacs N., and Nagy F. Morphometric changes of gray matter in Parkinson's disease with depression: a voxel-based morphometry study. Mov. Disord. 23 (2008) 42-46
79. Yoshikawa K., Nakata Y., Yamada K., and Nakagawa M. Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J. Neurol. Neurosurg. Psychiatry 75 (2004) 481-484
80. Chan L.L., Rumpel H., Yap K., Lee E., Loo H.V., Ho G.L., Fook-Chong S., Yuen Y., and Tan E.K. Case control study of diffusion tensor imaging in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 78 (2007) 1383-1386
81. Scherfler C., Schocke M.F., Seppi K., Esterhammer R., Brenneis C., Jaschke W., Wenning G.K., and Poewe W. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain 129 (2006) 538-542
82. Matsui H., Nishinaka K., Oda M., Niikawa H., Komatsu K., Kubori T., and Udaka F. Depression in Parkinson's disease. Diffusion tensor imaging study. J. Neurol. 254 (2007) 1170-1173
83. Matsui H., Nishinaka K., Oda M., Niikawa H., Kubori T., and Udaka F. Dementia in Parkinson's disease: diffusion tensor imaging. Acta Neurol. Scand. 116 (2007) 177-181
84. Becker G., Seufert J., Bogdahn U., Reichmann H., and Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 45 (1995) 4-182
85. Berg D., Siefker C., and Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J. Neurol. 248 (2001) 684-689
86. Walter U., Niehaus L., Probst T., Benecke R., Meyer B.U., and Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 60 (2003) 74-77
87. Stockner H., Sojer M.K.K.S., Mueller J., Wenning G.K., Schmidauer C., and Poewe W. Midbrain sonography in patients with essential tremor. Mov. Disord. 22 (2007) 7-414
88. Walter U., Prudente-Morrissey L., Herpertz S.C., Benecke R., and Hoeppner J. Relationship of brainstem raphe echogenicity and clinical findings in depressive states. Psychiatry Res. 155 (2007) 67-73
89. Berg D., Becker G., Zeiler B., Tucha O., Hofmann E., Preier M., Benz P., Jost W., Reiners K., and Lange K.W. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53 (1999) 31-1026
90. Berg D., Roggendorf W., Schröder U., Klein R., Tatschner T., Benz P., Tucha O., Preier M., Lange K.W., Reiners K., Gerlach M., and Becker G. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch. Neurol. 59 (2002) 999-1005
91. Walter U., Wittstock M., Benecke R., and Dressler D. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J. Neural Transm. 109 (2002) 191-196
92. Spiegel J., Hellwig D., Möllers M.O., Behnke S., Jost W., Fassbender K., Samnick S., Dillmann U., Becker G., and Kirsch C.M. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 129 (2006) 1188-1193
93. Berg D., Merz B., Reiners K., Naumann M., and Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov. Disord. 20 (2005) 345-383